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Summary
Fibrous cap rupture of a carotid atherosclerotic plaque leads to a transition from a stable to an unstable atherosclerotic plaque and is the etiology of a stroke. In a translational model for plaque rupture and utilizing ultraperformance liquid chromatography tandem mass spectrometry, the sera of patients presenting acutely with a symptomatic carotid-related transient ischemic attack or stroke (n=21) were found to have lower RvD1 and DHA levels compared to patients with asymptomatic carotid disease (n=24). ROC curve analysis showed that the serum ratio AA:RvD1 and AA:DHA represent a circulating pro-inflammatory lipid profile that is associated with acutely symptomatic carotid disease and stroke. Future work with validate further if these could be biomarkers for the risk of atherosclerotic plaque rupture.
Introduction
Atherosclerotic plaques arise in the vessel intima and media and are thought to be a result of cholesterol deposition, hemodynamic strain, and inflammation [1] . Rupture of the fibrous cap leads to a transition from a stable to an unstable atherosclerotic plaque. This plaque rupture results in clinically relevant sequelae: in the coronary bed, an atherosclerotic plaque rupture leads to myocardial infarction and, in the carotid artery, to an ocular or cerebral ischemic event. These latter events manifest as amaurosis fugax, transient ischemic attacks, or stroke. There is a need for biomarkers that can be used by clinicians to diagnose the potential rupture of atherosclerotic plaques.
Gaps in knowledge remain in the mechanisms leading to acute symptomatic atherosclerotic plaque rupture. Increasing evidence suggests that unresolved inflammation contributes to the development of plaque rupture [2] [3] [4] . Endogenous omega-3 and omega-6 polyunsaturated fatty acids (ω3-PUFAs and ω6-PUFAs) and their metabolites likely play crucial roles in atherosclerotic rupture-associated chronic inflammation.
Supplementation with ω3 docosahexaenoic acid (DHA)-rich fish oil results in fibrous cap thickening and stabilization [5] . We previously demonstrated that carotid plaques from neurologically symptomatic patients are inflammatory and have decreased intra-plaque levels of ω3 fatty acids, including DHA [4] . Consistent with this observation, resolvin D1 (RvD1, 7S, 8R, 17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, 19Z-docosahexaenoic acid), a potent inflammation-resolving lipid mediator biosynthesized from DHA, was reported recently to promote plaque stability, including decreased lesion oxidative stress and necrosis, improved efferocytosis, and fibrous caps thickening [2] . Resolvins, including RvD1, are inflammation-resolving mediators initially uncovered in the resolution phase of inflammation. DHA-derived RvD1 contributes to the atherosclerotic plaque stabilization by DHA [2] . Arachidonic acid (AA) is the major ω6 PUFA in humans and animals. AA is converted to a large array of short-lived pro-inflammatory eicosanoids including thromboxane A4, leukotriene B4, and sulfido-peptide leukotrienes and generally thought to promote inflammation. We aimed to determine whether circulating serum RvD1, DHA, and AA levels represent the risk of atherosclerotic plaque rupture.
Materials and Methods

Study Design
Patients with ≥ 50% internal carotid artery stenosis undergoing carotid endarterectomy (CEA) were included in this study. Informed consent was obtained after approval through the Ochsner Clinic Institutional Review Board. For each enrolling patient, the age, sex, history of cardiac disease, chronic renal insufficiency
recorded, as well as current medication use (antiplatelet, oral hypoglycemic, antihypertensive, or lipidlowering). Any previous ipsilateral ischemic symptoms, including time from onset were also taken into account.
Carotid plaque stability was determined on the basis of presenting symptomatology, confirmed by imaging (magnetic resonance imaging and/or computed tomography angiography imaging of the brain). Asymptomatic patients with high-d t d t (≥ 80% internal carotid stenosis based on duplex ultrasound imaging)
were included in the stable or asymptomatic carotid atherosclerotic plaque group. Patients presenting with symptoms of temporary or partial/complete loss of vision, a transient ischemic attack, and/or an established stroke with good neurologic recovery in the index hospitalization and deemed safe to undergo CEA were included as urgent or unstable carotid plaques [6] . The cohort included 24 asymptomatic and 21 acutely symptomatic patients deemed candidates for an urgent carotid endarterectomy (CEA) during the index hospitalization [7] ; mean time to intervention for acute interventions was 2.6 days ( Table 1) .
Lipid extraction and LC-MS/MS-based lipidomic analysis
The sera were isolated by centrifugation from the fasting peripheral blood of human patients who were 
Statistical analysis
All data were presented in average ± standard error of the mean (SEM) and analyzed using 
Results
Optimization of LC-MS/MS for lipidomic analysis of patients' sera
We extracted lipid mediators using methanol and solid phase extraction (SPE) technique as descried previously [12] . SPE usually yields better recovery and cleanup of analysts than liquid-liquid extraction alone. We used LC MRM-MS/MS methodology to analyze the serum extracts because it offers high sensitivity, reproducibility, and selectivity to analyze small molecules, including the compounds targeted in this report [22] [23] [24] [25] [26] . Supplementary Table 1 Table 1 and Supplementary Fig. 1 ), which allowed for the specific detection of each compound by LC MRM-MS/MS. The identification of RvD1 in sera was verified further by an MS/MS full-scan spectrum acquired from a larger volume of sera of patients ( Supplementary Fig. 2 ), which possessed diagnostic MS/MS ions of RvD1 as showed in the MS/MS spectrum of resolving D1 standard.
Resolvin D1 and ratio of arachidonic acid:resolvin D1 or arachidonic acid:docosahexaenoic acid: potential serum biomarkers for diagnosis of acutely symptomatic carotid plaques
Following the widely-used methodology to identify small molecules, including lipid mediators in the picogram range in physiopathological specimens [22] [23] [24] [25] [26] , we used the criterion that the compounds identified in a p t t' sera must have their LC MRM-MS/MS chromatographic retention times (within ± 0.1 min window) and signature MRM product ions match to those of the authentic standards. RvD1 was identified by this criterion (Supplementary Fig. 1 and Supplementary Table 2 ). However, other resolvins and lipoxin A 4 were only detected when their amounts reached the minimal detection limits in one or two samples, thus they were not considered for biomarker potentials. DHA and AA were also identified in abundant quantities in sera ( Supplementary Fig. 1 ).
Next, we quantified RvD1, AA, and DHA based on their LC MRM-MS/MS chromatographic peak areas, extraction recoveries, and linear calibration curves (Table 2) . LC MRM-MS/MS chromatographic peak quantification of RvD1, AA, and DHA revealed that sera RvD1 concentrations were 82 ± 11 pM for acutely symptomatic (urgent) vs. 152 ± 17 pM for asymptomatic carotid patients (p = 0.001). Additionally, DHA (precursor of RvD1 biosynthesis) was lower in the sera of urgent, compared to asymptomatic carotid patients (0.052 ± 0.007 M versus 0.076 ± 0.008 M, p = 0.025). However, the serum concentration of AA, a major -6
PUFA, was higher in asymptomatic vs. urgents (0.429 ± 0.046 M versus 0.257 ± 0.035 M, p < 0.01). RvD1 concentration provided the strongest correlation for urgent status (p < 0.01); high levels occurred in stable plaques, while low levels occurred in the acute rupture. Note that AA and DHA are much more prominent in the sera as these are in the M range, compared to RvD1, which is detected in the pM range.
Next, we investigated whether the sera concentration ratio of AA:DHA, AA:RvD1, and DHA:RVD1 could discern differences between the urgent and asymptomatic groups.
To investigate whether the concentration ratio of AA:DHA, AA:RvD1, DHA:RVD1, in the sera also could manifest differences between the acutely symptomatic and asymptomatic groups, we compared these ratios.
The ratios of AA:DHA and AA:RvD1 were associated with urgent; both were higher in the sera of acutely More interestingly, we found that combining two concentration ratios improved the ability of predicting carotid plaque rupture. Using the sum of the Z scores of DHA:AA and the Z scores of RvD1:AA in ROC analysis, the AUC increases to 0.90 (0.8069, 0.9907, 95% CI), which is significantly greater than 50%. This combination may provide us a powerful multi-parameter prediction tool.
Discussion
Unresolved chronic inflammation is a major factor in atherosclerotic plaque rupture. Resolvins are endogenous inflammation-resolving lipid mediators that are triggered by inflammation, likely as a self-defense action. In instances where resolvins are not adequately expressed, a pro-inflammatory state dominates [2, [27] [28] [29] Furthermore, in the case of atherosclerosis, inflammation is a component that is associated with the development of atherosclerotic plaque rupture [1, 2] . Here we demonstrate that circulating resolvin levels correspond to carotid plaque stability. Utilizing a translational model of plaque rupture [30] , serum levels of RvD1 and DHA, a precursor of RvD1, were found to be markedly lower in patients presenting with acutely symptomatic plaque rupture events compared to patients with asymptomatic carotid disease. This correlates with our previous work demonstrating that acutely symptomatic plaques have a decreased content of antiinflammatory lipids, such as DHA [4] . dd t t m j ω6 PUF um b d d t t d t t higher ratios of AA/RvD1 or AA/DHA in the sera of acutely symptomatic carotid patients as compared to asymptomatic carotid patients. The mechanisms underpinning this observation deserves further study in the future.
As we searched for a biomarker of plaque rupture, we chose to focus on the concentration ratio of AA:RvD1 (pM:pM) in the sera because this incorporates the AA and RvD1 differences noted between the acutely symptomatic and asymptomatic carotid patients. This was confirmed by our observation that the AA:RvD1 ratio was significantly higher for asymptomatic patients than for acutely symptomatic patients (Fig.   1A ). The serum concentration ratio of AA:DHA had a similar trend. These ratios are unitless and dimensionless, which could reduce the systematic errors in the analysis of the lipids. Additionally, the ratio uses one value instead of two values, which could simplify the presentation of the lipid mediators in the patient sera. To further examine the predictive values of RvD1, AA, DHA, AA:RvD1, and AA:DHA, we performed ROC curve analysis to calculate the sensitivity and specificity in the differentiation of the acutely symptomatic from the asymptomatic carotid patients. This analysis indicates that AA:RvD1, RvD1, AA:DHA, DHA, or AA has the potential to be a biomarker for diagnosis. However, AA:DHA and AA:RvD1 had the highest AUC in ROC.
A power analysis shows that at 5% significance level, our cohort of 21 acutely symptomatic and 24 asymptomatic patients has a relative high power to detect the effect size in most lipid mediators and ratios.
Specifically, there is a power of: 0.92 for RvD1 samples, 0.82 for AA samples, 0.62 for DHA samples, 0.98 for the ratio of AA:DHA, 0.78 for the ratio of AA:RvD1, but low power of 0.08 for the ratio of DHA:RvD1.
Efficient biomarkers for early prediction and diagnosis of acute symptomatic plaques are lacking, which impedes the ability of physicians to promptly diagnose and treat patients presenting, with an atherosclerotic plaque rupture event. Minimizing the time between plaque rupture and treatment is critical in reducing the morbidity after a patient has sustained a stroke as select patients diagnosed within 3 hours are offered systemic thrombolysis with recombinant tissue plasminogen activator (tPA), which improves outcomes after stroke [31] . However, tPA utilization rates among acute ischemic stroke patients is less than 7%, mainly due to delay in diagnosis [7] . The novel RvD1-based biomarker candidates identified here aim to fill this gap. For example, a simple ELISA or other detection kits could be developed to quantify RvD1 in the sera and have the potential to minimize diagnostic delays, aid in patient selection for possible thrombolysis and intervention.
Furthermore, a serum biomarker predictive of plaque vulnerability and future stroke risk could also be helpful in the management of asymptomatic high-grade carotid stenosis. The stroke reduction benefit from CEA over medical therapy in patients with asymptomatic carotid disease is based on randomized controlled trials from the 1990s [32] . Since that time, however, both the safety of surgery (CEA) and medical management of carotid disease have improved [33] . Many now question which is the best therapy for the patient with asymptomatic high-grade carotid disease [33] . Identification of circulating inflammation-resolving lipid mediators could, hypothetically, be used to predict which individuals with high-grade asymptomatic carotid disease are at risk of plaque rupture and stroke. Thus, earlier identification could then be used to treat such patients with more intense medical therapy or with a prophylactic CEA.
Although our experimental results provide a preliminary demonstration of the capability of RvD1 as a biomarker for the diagnosis and prediction of acute symptomatic plaque ruptures, we need to further confirm these results on a larger population of patients. Other precursors or metabolites of resolvin biosynthesis and degradation pathways also may be unique biomarkers for this purpose, and therefore this deserves further exploration. The profiles of whole fatty acids and enzyme systems warrant a thorough study in future research;
this will help decipher the underlined mechanisms for our findings in this report. The LC-MS/MS based tools and protocols established in this report provide the basis for these future studies. These studies also will provide critical data that can facilitate the exploration of cellular and molecular mechanisms underlying RvD1 deficiency in the sera of acute symptomatic plaque patients. Future studies are needed to determine how these serum lipid profiles will aid in predicting carotid plaque vulnerability and how this could be incorporated into routine clinical practice. 
